加载中
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
收盘时
US$223.21
−US$3.79 · -1.67%
盘后
US$223.21
US$0.00 · 0.00%
10月13日 16:10 ET
盘中时间采用ET。市场数据可能有所延迟。
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
日内区间
当前US$223.21
52周区间
当前US$223.21
盘中时间采用ET。市场数据可能有所延迟。
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
日内区间
当前US$223.21
52周区间
当前US$223.21
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（EUR） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 6.92亿 EUR | 3.64亿 EUR | 2.67亿 EUR | 5117.4万 EUR | 777.8万 EUR |
| 销货成本 | 1.03亿 EUR | 4425.8万 EUR | 4439.5万 EUR | 1213.7万 EUR | 352.3万 EUR |
| 毛利 | 5.89亿 EUR | 3.19亿 EUR | 2.22亿 EUR | 3903.7万 EUR | 425.5万 EUR |
| 研究与开发 | 2.84亿 EUR | 3.07亿 EUR | 4.13亿 EUR | 3.8亿 EUR | 2.96亿 EUR |
| 销售、一般及管理费用 | 4.36亿 EUR | 2.85亿 EUR | 2.59亿 EUR | 2.16亿 EUR | 1.6亿 EUR |
| 营业费用 | 7.19亿 EUR | 5.98亿 EUR | 6.78亿 EUR | 6.01亿 EUR | 4.56亿 EUR |
| 利息收入 | 1469.71万 EUR | 1436.1万 EUR | 1685.7万 EUR | 742.6万 EUR | 69.2万 EUR |
| 利息支出 | 7746.41万 EUR | 6550.4万 EUR | 4406.5万 EUR | 3068.2万 EUR | 391.1万 EUR |
| 折旧和摊销 | 1699.76万 EUR | 1771.4万 EUR | 1891.1万 EUR | 1795.8万 EUR | 1539.1万 EUR |
| 营业利润 | −1.31亿 EUR | −2.79亿 EUR | −4.56亿 EUR | −5.62亿 EUR | −4.52亿 EUR |
| 净利润 | −2.19亿 EUR | −3.78亿 EUR | −4.81亿 EUR | −5.83亿 EUR | −3.84亿 EUR |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
T. Rowe Capital Appreciation Equity ETFTCAF1.75亿1.92%91.19亿 USD0.31%US$43.55-0.02%
iShares Biotechnology ETFIBB1.09亿1.01%108.2亿 USD0.44%US$200.02-2.08%
iShares Russell Mid-Cap Growth ETFIWP6422.24万0.32%200.95亿 USD0.23%US$140.45-0.38%
iShares Russell Mid-Cap ETFIWR5031.18万0.09%567.65亿 USD0.18%US$109.59+0.11%
iShares Russell 1000 Growth ETFIWF4324.06万0.03%1305.08亿 USD0.18%US$127.12-0.01%
Sapient Quality Select ETFSQS3213万2.26%14.19亿 USD0.80%US$28.3897-0.28%
Vanguard Russell 1000 Growth ETFVONG2013.05万0.04%543亿 USD0.06%US$130.82-0.05%
First Trust Health Care AlphaDEX FundFXH1482.72万1.32%11.13亿 USD0.61%US$129.89-0.76%T. Rowe Capital Appreciation Equity ETFTCAFiShares Biotechnology ETFIBBiShares Russell Mid-Cap Growth ETFIWPiShares Russell Mid-Cap ETFIWRiShares Russell 1000 Growth ETFIWFSapient Quality Select ETFSQSVanguard Russell 1000 Growth ETFVONGFirst Trust Health Care AlphaDEX FundFXHAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
